(Pisgah Forest, NC—May 17, 2011). Responding quickly to the FDA’s proclaimed new limits on acetaminophen in prescription painkiller combination products, Pisgah Laboratories, Inc., www.pisgahlabs.com files a patent application on abuse deterrent features for opioid drug products. Filed with the US Patent & Trademark Office (www.uspto.gov), this new patent application is the eighteenth filing for Pisgah and represents a substantial R&D effort directed toward a broad-based platform technology addressing the horrific effects of drug abuse.
Drug abuse has crept into every facet of global society with untold human costs and is an incalculable financial drain on a nation. Governmental efforts to stem drug abuse are essentially ineffective and recidivism high. At a time when the United States needs a “break”, drug abuse continues to squander human talent and resources, but Pisgah Labs’ scientists remain focused on reducing abuse of popular prescription drugs. Indeed, nearly one hundred and forty million prescriptions are written annually for hydrocodone in combination with acetaminophen (APAP).
Many of these products, containing APAP in large dosage amounts, are purported to cause liver toxicity and the FDA has established new limits for the amount of APAP allowed. The new rulings come at a favorable time in Pisgah’s product development cycle as they develop abuse deterrent hydrocodone / acetaminophen products.
Unlike older attempts to manipulate the abuse potential by formulation, Pisgah has scientifically addressed the abuse potential at the active ingredient level. Pisgah has identified new salt forms of hydrocodone which significantly improves its performance features compared with hydrocodone bitartrate currently used in the industry. Indeed, Pisgah has avoided the pitfalls often found in commercializing pro-drugs or relying solely on formulation techniques to solve complex problems. Pisgah has identified salt forms of nearly all the commercial opiates used in prescription pain medications which will impart abuse deterrent features. The drug abuser will find it more difficult to separate the active ingredient from the dosage form, and the active will be far less soluble in the abuse-route mucosa (nasal, vaginal, rectal). However, it is important to note, the drug will perform properly when used as intended by oral administration—and when taken as prescribed, the release of the drug is not accelerated by drinking alcohol.
As for an integrated commercial offering covering other popular pain medications, Pisgah is continuing their research efforts while aggressively pursuing a development program for hydrocodone / acetaminophen combination products. In laboratory testing, Pisgah has shown they can “adjust” the properties of the new salts to yield immediate or controlled release versions. In general, the drug development pathway can be quite tortuous with unexpected events occurring such as the FDA’s mandate to reduce acetaminophen levels in products like Pisgah is developing. Fortunately, Pisgah sees this change more as an opportunity than a difficulty. As Pisgah’s President, Bill Bristol commented, “The mandated lower levels of acetaminophen allows for our technology’s benefits to shine and not to be eclipsed by the health issues raised by higher levels of acetaminophen in combination products”.
With eighteen patent applications and more on the way, Pisgah’s intellectual property stable continues to grow, and is applicable to dozens of abused prescription drugs. Pisgah’s technology provides an integrated solution to three principal concerns within the medical community: 1) improving patient care, 2) reducing medical practice liability, and 3) reducing barriers for treating pain. Pisgah anticipates its new products will be well received by all stakeholders interested in reducing the Nation’s drug abuse epidemic.
For more information or to discuss licensing opportunities, please contact: Todd Stamps, Business and Market Development, 803-212-8224
(Pisgah Forest, NC - January 19, 2011) As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility. Accordingly, Pisgah’s pilot plant has recently undergone appropriate modifications to convert the often, and readily abused hydrocodone bitartrate currently used by the pharmaceutical industry to Pisgah’s abuse deterrent form. Pisgah’s approach to the abuse epidemic thwarts attempts by potential abusers to de-formulate hydrocodone products for abuse purposes.
Typically, abusers extract the active ingredient from a formulated dosage product. The principal extraction procedure popularly employed by hydrocodone abusers is the “cold water method”. The abuser grinds up the hydrocodone bitartrate / acetaminophen combination tablets and extracts them with a minimum amount of cold water to separate the insoluble and potentially toxic acetaminophen (APAP) from the water soluble hydrocodone bitartrate. The abuser then drinks the water extract and experiences a “high” or “rush”. In contrast, Pisgah’s hydrocodone salt is not amenable to such an extraction procedure and thus, defeats the abusers’ attempt to isolate the narcotic component from the dosage product.
Pisgah recently completed an alternate species animal study comparing inhalation properties of hydrocodone bitartrate with their abuse deterrent hydrocodone. The pharmacokinetic study clearly differentiated the two forms thus validating Pisgah’s approach in defeating nasal abuse of hydrocodone. Similarly, the study results also confirm proper oral administration allows for the drug to work as intended. These results, coupled with the extraction protection available through Pisgah’s technology, provide the first practical solution to hydrocodone drug abuse.
Pisgah’s product development program is now focused on clinical trial production. Since hydrocodone is principally used in combination products with other actives such as acetaminophen, Pisgah has selected dosage strengths of hydrocodone / APAP meeting the FDA’s new limits for acetaminophen, http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm165107.htm, and comparable to existing commercial products so that side-by-side abuse deterrent comparisons can be performed. One study in particular, called a likability study will be performed using known “recreational” users. From results to date, these users will predictably find Pisgah’s hydrocodone “un-likable”. Indeed, inhalation or other abuse routes of administration—such as application to the mucosa—will not yield the desired “high”.
Pisgah Laboratories continues to file patent applications covering the broad applicability of their technology to hydrocodone as well as to other narcotic products. At last count, fourteen applications were in various states of prosecution before the US Patent and Trademark Office covering opioids, anti-depressants and the ADHD medications, dex-amphetamine and methylphenidate. While hydrocodone has advanced from the laboratory into the development stage, other abuse deterrent products will soon follow an identical and established development template.
Pisgah’s technology provides an integrated approach to solving three principal concerns within the medical community: 1) improving patient care, 2) reducing medical practice liability, and 3) reducing barriers for treating pain. Clearly, abuse deterrent products improve the health of the Nation’s population by reducing drug abuse. Secondly, the regulatory initiatives to reduce abuse impose liability on the medical community requiring identification and mitigation of patient drug abuse. Without exception, these well-intended actions erect barriers to pain treatment for legitimate patients and enhance the perceived liability of doctors. Pisgah anticipates its new products will be well received by all stakeholders interested in reducing the Nation’s drug abuse epidemic.
For more information on Pisgah’s pipeline, visit www.pisgahlabs.com or call:
Todd Stamps @ 803-212-8224 Business and Market Development
(Pisgah Forest, NC—December 8, 2010) Pisgah Labs announced today the findings from a proof of concept study confirming Pisgah’s technology imparts abuse deterrence to commonly abused prescription drugs, particularly narcotics. The controlled study, conducted in dogs, was performed with the un-formulated active ingredient, hydrocodone, as modified according to a host of patent applications filed by Pisgah Labs with the United States Patent and Trademark Office (www.uspto.gov). Marketed hydrocodone products are highly susceptible to abuse and indeed, hydrocodone represents the most highly abused pain medication in the country. Since Pisgah’s technology converts the active ingredient to an abuse-deterrent form, the controlled study was performed using Pisgah’s abuse deterrent hydrocodone compared with hydrocodone bitartrate which is exclusively marketed by pharmaceutical companies.
With the study’s performance evaluations done on the un-formulated active ingredients, a direct comparison was made between the two forms of active ingredient. The findings from the study confirmed Pisgah’s technology is a superior choice over the existing hydrocodone bitartrate for providing abuse deterrence.
Hydrocodone is most often abused by first extracting the active ingredient from the formulated product, then using the enriched opioid to get high. Hydrocodone isolated from existing commercial products provides a powerful “high” to the abuser since the enriched active is highly soluble in the mucosal membranes—like those found in the nose. With Pisgah’s hydrocodone, the opioid has been modified at the active ingredient level to prevent or inhibit both the extraction process from the formulated product and if extracted, to absorb slowly in the nasal mucosa so that an abuser does not get high—just highly disappointed.
In regard to the study, dogs were ideal to demonstrate the advantage of Pisgah’s modified hydrocodone versus the commercial alternative. Dogs were chosen because of their high nasal surface area which would provide the highest sensitivity and differentiation between the two opioid forms. The intranasal dosing was also compared, to results from oral dosing. The pharmacokinetic (PK) data was acquired for the opioid forms for both dosing regimens and the matrix comparisons performed for the two types of hydrocodone active ingredient. As was expected, hydrocodone bitartrate was readily absorbed through the nasal tissues and rapidly reached maximum blood concentrations as compared with Pisgah’s version of the active ingredient. With Pisgah’s hydrocodone, the intranasal application yielded a much slower rate of absorption into the blood stream with a lower Cmax occurring at nearly an hour after dose administration. Simply stated, Pisgah’s hydrocodone exhibits abuse deterrence when administered nasally.
The study findings from the oral administration were equally encouraging. Pisgah’s hydrocodone active ingredient was designed to have immediate release characteristics like those of hydrocodone bitartrate, yet still remain abuse deterrent. Indeed, the two forms had similar oral release profiles except thePisgah hydrocodone, immediatelyafterdose administration,exhibited an induction period before attaining the same release rate as the bitartrate salt. In fact, Pisgah’s hydrocodone exhibited performance characteristics representing the best outcome possible: intranasal administration confirmed abuse deterrent features while oral administration can be subjected to formulation techniques to yield an immediate release or extended release drug product.
Pisgah is currently engaged in final dose product development employing their patent pending technology and will soon be submitting the necessary regulatory filings to the FDA. Their technology represents a global solution to the abuse of opioid based narcotics and to the often abused attention deficit / hyperactivity disorder (ADHD) medications such as amphetamine and methylphenidate. For more information on Pisgah’s technology and licensing opportunities visit www.pisgahlabs.com or call the contact listed below.
Contact: Todd Stamps
Business Development and Licensing
803-212-8224
PISGAH FOREST, NC, November 4, 2010. Pisgah Labs, Inc., an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant. The Qualifying Therapeutic Discovery Project Program made funding available to promising new technologies ready for pre-clinical or clinical trials, and to support filing of a New Drug Application (NDA) with the United States Food and Drug Administration. Pisgah Labs solicited the grant monies in order to accelerate their abuse deterrent technology incorporated into their first product, hydrocodone. The grant will be used to fund on-shore pre-clinical and clinical trials in furtherance of Pisgah’s FDA filing for an abuse-deterrent form of hydrocodone.
The Nation is experiencing a prescription drug abuse epidemic - a condition highly detrimental to the abuser, a burden on society and one incurring huge costs to our infrastructure. Hydrocodone is a medically necessary pain medication and with over one hundred million prescriptions annually, it’s the most abundantly prescribed narcotic. Consequently,and not surprisingly, it’s the most abused narcotic inthe Country.
Pisgah Labs’ technology platform addresses these global problems in the context of the FDA’s drug safety initiative (REMS). The methodology operates at the active ingredient level by forming a specialized salt form of the opiate. The desired abuse deterrent performance features provide the first line of defense against abuse and dosage formulation techniques may (optionally) provide additional abuse deterrent features.
In laboratory tests, Pisgah’s technology prevents hydrocodone solubility in the pH range common for mucosal abuse and hence, abuse pathways are mitigated. Further, benefits arise from the material’s poor solubility in organic solvents and in particular, ethanol does not accelerate the inherent dissolution profile. Initial product formulation efforts employing the Pisgah technology incorporates a chemical marker for an out-of-package “track and trace” system useful by law enforcement in the controlled substance supply chain. The in vitro tests also demonstrate the ability to provide efficacious and medically necessary drug products while simultaneously inhibiting drug misuse, abuse or tampering.
Pisgah plans to utilize the grant monies for further refinement of the formulated dosage product, to prepare clinical trial materials and to execute clinical trial protocols designed to demonstrate bioequivalence with existing commercial products (principally, through cross-over pharmacokinetic studies). More importantly, and to which the benefit of the technology may be realized, Pisgah plans to conduct “likability” studies in opiate tolerant / drug abusers to confirm the in vivo results correlate with the in vitro laboratory findings.
As Pisgah proceeds with its drug product development pipeline of abuse deterrent products, Pisgah recognizes the importance of partnering with interested companies to bring innovative and novel products to the marketplace which have a huge societal impact. Currently, Pisgah is in intellectual property licensing negotiations with several prominent pharmaceutical companies to discuss how Pisgah’s technology could accelerate market access toabuse deterrent forms of the morecommonlyabused pain and attention deficit / hyperactivity disorder (ADHD) medications. Besides the abuse potential associated with pain relief medications such as hydrocodone, oxycodone and similar narcotics, methylphenidate and amphetamine, which are commonly used for ADHD treatment, are also reported to have high abuse rates. New abuse deterrent drug products for ADHD based on Pisgah’s technology are in progress and development efforts have yielded promising results.
In addition to their product development program, Pisgah anticipates additional patent allowances soon supporting its commercial efforts and the broader foray into abuse-deterrent products. To learn more about these opportunities and Pisgah’s technology licensing program, visit www.pisgahlabs.com
Contact: Todd Stamps Business Development & Licensing Rx Abuse Deterrent Technologies 803-212-8224
PISGAH FOREST, NC, Aug. 17, 2010. Today, Pisgah Labs, Inc. (www.pisgahlabs.com) received a Notice of Allowance from the United States Patent and Trademark office (http://www.uspto.gov/) for an important new technology patent addressing global stability problems of thyroid hormone drugs. According to the FDA (http://www.fda.gov/): “Thyroid hormones effect protein, lipid, and carbohydrate metabolism, growth and development. Orally administered levothyroxine sodium is used as replacement therapy in conditions characterized by diminished or absent thyroid function, such as cretinism, myxedema, nontoxic goiter, or hypothyroidism. Levothyroxine sodium may be used to suppress the secretion of thyrotropin in the management of simple nonendemic goiter, chronic lymphocytic thyroiditis, and thyroid cancer.”
The shelf life of important treatments, particularly for prescription drugs is a factor that affects all patients. A medication past its expiry date has been shown to have decreased potency to the extent it may no longer exhibit therapeutic value. Drug product manufacturers in conjunction with the FDA routinely perform and monitor the stability offormulated drugproducts and of theactive ingredients usedto make those drug products. In the case of the thyroid hormones, the stability of the existing commercial drugs is inherently lacking and formulation techniques do little to correct the deficiency. Current manufacturers have responded to the FDA’s insistence for safe and efficacious medications, but breakthrough technology was, until now, unavailable.
Further, the criticality of drug product stability and associated shelf life is obviously very important and well exemplified when considering the low-dose requirements of the thyroid hormone drugs. During the past decade, the FDA implemented rigorous potency standards for thyroid related drug products such as Synthroid®, Unithroid®, Levothroid®, Levolet® and Levoxyl®. The very low dosage needed for therapeutic effect was susceptible to potency degradation during and after manufacturing, and the low dosage challenged manufacturing techniques for provision of a uniform tablet-to-tabletdosage.Endocrinologists know a patient being treated for hypothyroidism could experience the complete range of dosing—from an ineffective dose to an overdose—principally due to the instability of levothyroxine (T4) or liothyronine (T3).
In response to the potency variability, manufacturers employed various formulation techniques to improve the stability of these delicate and sensitive active ingredients. Regulatory mandates can typically only serve as patches to inherent problems when invention is required to completely resolve a serious problem. The FDA’s effort to narrow the release specification for these products defined an outcome, but not a means by which the desired result could be routinely obtained. Not surprisingly, the industry has remained handicapped with product quality often jeopardized. At the root of the stability and potency issue was a need to improve the inherent stability of the active ingredients prior to their formulation into dosage products.
Fortunately, Pisgah Labs has prepared thyroid hormone active ingredients in salt forms which exhibit unprecedentedstability. Since the improved stability occurs at the active ingredient level, formulation demands are significantly lessened. With improved active ingredient stability, the formulation and manufacturing requirements are comparatively uncomplicated and can principally address the dosage and batch-to-batch uniformity.
Pisgah Labs is currently employing this and related technologies in drug product development activities which enhance the physical and chemical performance features of existing active ingredients and drug products. In a related area of intellectual property, Pisgah has identified a platform technology for imparting abuse deterrent features to the highly abuse opioid-base products such as hydrocodone, oxycodone, morphine, hydromorphone and oxymorphone.For those interested in additional information, please visit www.pisgahlabs.com
PISGAH FOREST, NC, June 28 PRNewswire/- Pisgah Labs, Inc. a drug product development company and an active pharmaceutical ingredient manufacturer is pleased to announce the May 18, 2010 issuance of US Patent 7,718,649. This patent culminates several years work and investment by Pisgah Labs, Inc. ( http://www.pisgahlabs.com) to demystify the physical states of Imipramine Pamoate drug substances. The patent also covers methods of manufacturing, purifying and use of the drug in pharmaceutical preparations, and marks the first allowance in a related series of applications pending before the UnitedStates Patent and Trademark Office (USPTO) (http://www.uspto.gov/main/patents.htm).
Further, Pisgah will soon file on its discoveries regarding abuse-deterrent formulations for the treatment of Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD). In the past few years the Food and Drug Administration (FDA) ( http://www.fda.gov) has assertively engaged pharmaceutical companies to address America’s drug abuse epidemic as guided by theFDA’sRisk Evaluationand Mitigation Strategy (REMS) initiative. Pisgah’s patent filing regarding AD(H)D drugs is timely given the significant abuse of this disorder’s treatment medications. FDA has announced a 2-day public meeting to obtain input from stakeholders who have raised concerns about the impact of REMS on the healthcare system including prescribers, pharmacists and other affected stakeholders ( http://www.fda.gov/Drugs/NewsEvents/ucm210201.htm).
The industry’s challenge is to provide medically necessary products such as ADHD medications yet impede abuse. Pisgah’s technology enables the drug to perform properly when used for the intended medical purpose, yet perform poorly when abused or misused. Inaddition to basic abuse deterrent features, Pisgahhas refined their technology to yield products which are unaffected by alcohol consumption. Pisgah’s technology is also applicable to a host of opioid controlled substances. Since the technology relies on salt formation, essentially any controlled substance containing a basic nitrogen will succumb to conversion to an abuse deterrent form. Therefore, a predictable product development cycle for abuse deterrent products is available to narcotics such as oxycodone, hydrocodone, morphine, oxymorphone, hydromorphone and methadone.
Law enforcement and supply chain security are also addressed within Pisgah’s technology. The platform affords a forensic methodology for addressing drug trafficking, diversion, counterfeiting and crime scene analysis by imparting a track-and-trace capability. This feature covers the actual active ingredient, and formulations can be adjusted to provide a chemical “fingerprint” for a specific manufacturer. A simple analysis will be sufficient for the DEA to determine if the drug was illegally diverted (and from where) or for Customs to determine if the drugis a counterfeit. It would appear Pisgah’s multi-level, abuse deterrent platform is a promising route to alleviating drug abuse which continues to increase at an alarming rate in America.
Pisgah’s technology is based on new salt forms of active ingredients exhibiting well-known patient safety and efficacy. However, the new salts demonstrate medicatious release when used as intended, but the saltlacks sufficientsolubility in themucosal membranes andwon’t afford the“high” when abused. This feature also complicates the extraction of the active ingredient from the formulated dosage, and unlike other products on the market, crushing the tablet has no effect on releasing the controlled substance (for abuse).
Pisgah has advanced their technology platform to the final dose product development stage in preparation for FDA regulatory filings. Currently, Pisgah is seeking partnerships or licensing agreements to rapidly introduce these important products which will improve patient safety and health for all Americans.
Contact: Todd Stamps 803-212-8224 or tstamps@pisgahlabs.com
PISGAH FOREST, NC – March 26, 2010. Pisgah Labs, a drug product development companyand an active pharmaceutical ingredient manufacturer (API) located in western North Carolina has received a patent allowance in a series of patent applications. The US Patent & Trademark Office (USPTO) has notified Pisgah Labs, Inc. (www.pisgahlabs.com) that a patent application related to a therapeutically significant family of pharmaceutical polymorphic compositions of imipramine pamoate has been allowed. The patent application also includes methods of manufacturing, purifying and use in pharmaceutical preparations.
Interestingly, imipramine is reported to exhibit therapeutic benefit besides the treatment of depression. Imipramine has been used in the treatment of fibromyalgia, childhood nocturnal enuresis and other types of urinary incontinence, trichotillomania, post-traumatic stress disorder, panic disorder and to provide analgesic-like relief for neuropathicpain. Researchers have reported a relationship between imipramine binding, serotonin uptake and the link between fibromyalgia and depression. Medical treatments for fibromyalgia are well documented on the University of Maryland Medical Center’s website:
http://www.umm.edu/patiented/articles/what_medical_treatments_fibromyalgia_000076_10.htm.
In regard to imipramine pamoate, used in the well known product, Tofranil PM®, some may say activity level required was disproportionate to the achievement. “Not so” says Pisgah’s president, Bill Bristol. “From what we learned while focused on this imipramine we have leveraged this knowledge into a new business opportunity for the Company. Our discoveries led to additional patent filings related to abuse-deterrent prescription drugs like oxycodone and hydrocodone. We realized we could apply our findings to pain products to achieve selective dissolution profiles. From our early work with imipramine, we’re now heavily engaged in developing abuse-deterrent forms of narcotics including hydrocodone—the most abused drug in America”.
Pisgah Labs’ intellectual property development has led to more than ten filed applications related to market and regulatory desirable performancefeatures like ineffectiveness when snorted or injected; and grinding or chewing has no effect on accelerating active ingredient release. Extraction of the active, or to practice adangerous abuse route called “dose dumping” is dramatically hindered. Observations so far indicate the chemistry is applicable to all of the potentially abused drugs. Pisgah is activelydeveloping a product stable of anti-abuse opioid products and breathing life into medically necessary, but often abused pain medications.
Pisgah anticipates additional patent allowances soon supporting its commercial (imipramine) efforts and the broader foray into abuse-deterrent products. To learn more about these opportunities and Pisgah’s technology licensing program, visit www.pisgahlabs.com
Contact: Todd Stamps 803-212-8224 tstamps@pisgahlabs.com
PISGAH FOREST, N.C., Jan. 12, 2010 – According to the Office of National Drug Control Policy (http://www.whitehousedrugpolicy.gov/), prescription drug abuse is more prevalent than abuse of cocaine, heroin and methamphetamine. In fact, in the past year, prescription drug abuse ranked second only to marijuana use. In the face of this growing problem, Pisgah Labs, Inc. (http://www.pisgahlabs.com) has just filed its eighth patent application on a technology that promises to curb prescription drug abuse.
While large pharmaceutical companies have been unable to stop abuse of their prescription drugs -- particularly opiate-baseddrugs -- Pisgah Labs has beenquietly working behindthe scenes to create ananti-abuse chemical methodology that will work with the pain medications most often abused in the U.S. Now, with its eighth patent application filed on the technology, Pisgah Labs is working on receiving FDA approval to conduct clinical trials on the anti-abuse technology -- the company’s first offering in a lengthy product pipeline. The goal: to demonstrate the technology will interrupt and prevent drug abuse throughout the supply chain.
In developing its technology, Pisgah Labs focused on the six basic factors it says are necessary to reduce drug abuse. That focus paid off: The company’s research and development has yielded a tamper-proof technology capable of containing multiple mechanisms to inhibit abuse. With the technology, the active ingredient in a prescription drug cannot be easily or cheaply extracted. The anti-abuse properties are not defeated by chewing, grinding or otherwise physicallymanipulating the prescription drug. What’s more, when combined with Pisgah Labs’ anti-abuse technology, a drug’s active ingredient release rate is unaffected by alcohol consumption, rendering abusersunable to “dose dump” on demand by consuming alcohol in conjunction with the drug. The technology even has a built-in track-and-trace feature. But perhaps most importantly, while allowing a prescription drug to work as intended when taken as directed, Pisgah Labs’ anti-abuse technology causes the drug to not work at all when abused.
“In general, routes of abuse administrationstart with the abilityto defeat the modified release properties the drug product contains or to circumvent the chemical and mechanical barriers intentionally designed into theproduct,” explained Bill Bristol, president and CEO of Pisgah Labs. “Pisgah’s platform technology addresses the drug abuse issue at the active ingredient level, which is then formulated into the actual dosage medication as a tablet or capsule. In this manner, the principle anti-abuse property starts at the molecular level with the active ingredient. Formulation can then provide additional defensive barriers to abuse.”
In other words, if Pisgah Labs has anything to say about it, it won’t be long before prescription drug abuse is on a steep decline. Though it still has to demonstrate clinical results to the FDA, the company is confident its patent-pending anti-abuse technology is up for the challenge. To learn more, visit http://www.pisgahlabs.com.
Contact: Dr. Cliff King Pisgah Labs, Inc. 828-884-2789 x223 crking@pisgahlabs.com